Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (ZBH) is a global innovator in musculoskeletal healthcare, delivering advanced orthopedic solutions for nearly a century. This news hub provides investors and medical professionals with timely updates on product developments, regulatory milestones, and strategic initiatives shaping the future of surgical care.
Track critical updates including quarterly earnings, FDA clearances for robotic surgery systems, and partnerships advancing AI-driven orthopedic solutions. Our curated feed consolidates press releases about joint reconstruction technologies, trauma care innovations, and global market expansions to inform your analysis of this medtech leader.
Discover how Zimmer Biomet’s integration of digital surgery platforms with traditional orthopedic expertise continues to redefine patient outcomes. Bookmark this page for direct access to verified updates about ZBH’s clinical advancements, without promotional commentary or speculative content.
Zimmer Biomet introduced new artificial intelligence capabilities in its Omni Suite, aimed at enhancing surgical workflow efficiency. This intelligent operating room solution automates manual tasks, providing real-time workflow metrics through automatic recognition of key milestones, such as patient entry and anesthesia timing. The AI feature complements the existing ZBEdge technology, enhancing patient outcomes and surgical experiences. Currently available in the United States, the Omni Suite demonstrates Zimmer Biomet's commitment to innovation in medical technology.
Zimmer Biomet Holdings, Inc. (ZBH) reported first quarter 2022 net sales of $1.663 billion, marking a 3.9% increase year-over-year. Adjusted diluted earnings per share were $1.61, while diluted earnings per share stood at $0.35.
The company raised its full-year guidance, now projecting revenue growth of (1.5)% to 0.5% and adjusted diluted EPS of $6.65 to $6.85. The spinoff of ZimVie was completed on March 1, 2022, and notable innovations such as WalkAI™ were launched, enhancing the company's digital offerings.
Zimmer Biomet Holdings (NYSE: ZBH) will present at the BofA Securities Healthcare Conference on May 11, 2022, at 5:00 p.m. Eastern Time. The presentation will feature Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay. A live webcast will be available on the company's Investor Relations website and will be archived for later viewing. Zimmer Biomet is a leader in medical technology, focused on enhancing mobility and health through innovative products.
ZBH has scheduled its first-quarter earnings conference call for May 3, 2022, at 8:30 a.m. ET. A news release detailing financial results will be published at 6:30 a.m. ET on the same day. Investors can access the live audio webcast via the Investor Relations website. The conference call offers a dial-in option for participants in the U.S. and Canada. The archive of the webcast will be available post-conference. Zimmer Biomet operates in over 25 countries and sells in more than 100 countries.
Zimmer Biomet Holdings (ZBH) has launched WalkAI, an innovative AI model designed to predict patients' gait speed outcomes 90 days post-hip or knee surgery. Utilizing a proprietary algorithm and data from the ZBEdge database, WalkAI offers daily personalized predictions, helping healthcare professionals identify patients who may not follow typical recovery patterns. This model enhances patient care management through the mymobility platform and represents a significant step in Zimmer Biomet's AI strategy.
Zimmer Biomet Holdings announced the successful spinoff of ZimVie, its former Dental and Spine business, effective March 1, 2022. ZimVie will commence trading on Nasdaq under the symbol 'ZIMV.' Shareholders received one ZimVie share for every ten Zimmer Biomet shares held as of February 15, 2022. Bryan Hanson, CEO, emphasized that this strategic move is expected to enhance revenue growth and create shareholder value for both Zimmer Biomet and ZimVie. The spinoff distributes 80.3% of ZimVie's shares to existing Zimmer Biomet shareholders, with proceeds from fractional shares sold in the market.
ZimVie will replace Tabula Rasa Healthcare in the S&P SmallCap 600 index on March 2, 2022. This change comes as Zimmer Biomet Holdings spins off ZimVie, effective March 1, 2022. Post spin-off, Zimmer Biomet will continue to be a part of the S&P 500 index. Tabula Rasa Healthcare is being removed due to its lack of representation in the small-cap market.
Zimmer Biomet Holdings has announced a quarterly cash dividend of $0.24 per share for the first quarter of 2022. This dividend will be payable on April 29, 2022, to stockholders who are on record as of March 29, 2022. The company continues to position itself as a leader in medical technology, providing innovative products aimed at improving health and mobility. With a legacy spanning over 90 years, Zimmer Biomet strives to enhance the patient experience through its advanced digital and robotic technologies.
ZimVie, set to be a standalone publicly traded company from Zimmer Biomet (NYSE: ZBH), held its first Investor Day on February 7, 2022. The event highlighted its Spine and Dental offerings, market opportunities, and financial strategy. For 2022, ZimVie projects revenues of $1.0 billion, maintaining levels from 2021, with an adjusted EBITDA margin of 13.1% to 13.6%. Adjusted EPS is forecasted between $2.10 and $2.30. The ongoing COVID-19 pandemic presents risks to these projections as ZimVie aims to innovate within the $20 billion global dental and spine markets.
Zimmer Biomet Holdings has announced a dividend distribution of 80.3% of ZimVie Inc. shares to its shareholders on record as of February 15, 2022. Each shareholder will receive one share of ZimVie for every ten shares of Zimmer Biomet they own. The distribution will occur on March 1, 2022, with no fractional shares given; instead, fractional shares will be sold, and proceeds distributed as cash. ZimVie will begin 'when-issued' trading on NASDAQ on February 14, 2022, under the symbol 'ZIMVV'. Regular trading of ZimVie is set for the distribution date under 'ZIMV'.
